Video

ARVO LIVE: OTT166 in the treatment of diabetic retinopathy

Author(s):

David Hutton,Martin David Harp
Conferences|ARVO

Ophthalmology Times® talked with David Tanzer, MD, about OcuTerra Therapeutics and their development of OTT166 in the treatment of diabetic retinopathy.

Ophthalmology Times® talked with David Tanzer, MD, about OcuTerra Therapeutics and their development of OTT166 in the treatment of diabetic retinopathy.

Video transcript

Editor’s note: Transcript lightly edited for clarity.

Related Videos
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
Vikas Chopra, MD, at AAO 2024: The role of MIGS in earlier intervention and safer techniques
AAO 2024: Weijie Violet Lin, MD, discusses risk factors for epithelium-off cross-linking
Related Content
AAO 2024: Ocular imaging in the emergency department can provide timely, accurate diagnosis
November 1st 2024

AAO 2024: Ocular imaging in the emergency department can provide timely, accurate diagnosis

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Life Biosciences reports advances in nonhuman primate studies on partial epigenetic reprogramming for restoring visual function
October 22nd 2024

Life Biosciences reports advances in nonhuman primate studies on partial epigenetic reprogramming for restoring visual function

Robert Chang, MD, discusses the impact of large language models on glaucoma care and AI in ophthalmology
November 5th 2024

Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD

AAO 2024: 3D printed eyeglasses bring vision care to children in underserved, remote communities
October 20th 2024

AAO 2024: 3D printed eyeglasses bring vision care to children in underserved, remote communities

AAO 2024: LiGHT trial shows SLT outperforms medications in reducing glaucoma progression over 6 years
October 20th 2024

AAO 2024: LiGHT trial shows SLT outperforms medications in reducing glaucoma progression over 6 years

© 2024 MJH Life Sciences

All rights reserved.